ARVN

6.5303.12%
AM

Angela M. Cacace

Chief Scientific Officer

Ms. Angela M. Cacace, Ph.D., is Chief Scientific Officer at Arvinas, Inc. since June 17, 2024 and was its Senior Vice President of Neuroscience & Platform Biology from January 2022 to June 2024. Dr. Cacace joined Arvinas in 2018. She was Senior Vice President of Neuroscience, Platform Biology & the Platform Accelerator Therapeutics Hub of Arvinas, Inc. from 2018 to January 2022. She served as Vice President of Neuroscience and Platform Biology at Arvinas Holding Company, LLC since September 2018 and served as Vice President of Biology at Fulcrum Therapeutics, Inc. since April 2016 until September 2018. Ms. Cacace joined Fulcrum Therapeutics, Inc. in 2016. She served as a Director of genetically defined diseases at Bristol Myers Squibb (BMS) since August 2007 until April 2016, leading a biology team focused on genetic neurologic and skeletal muscle disorders. Also while at BMS, she served as Director of exploratory neurosciences and applied genomics and established and led teams that worked across research, including the Cellular Resource Group, the GPCR Hit Identification Group and the Lead Profiling (ADMET) Teams. She served as Senior Principal Scientist in Cancer Biology at Pfizer Inc. from September 2006 to August 2007. She has experience in pharmaceutical research contributing to the early discovery of 16 molecule and their advancement into clinical development. Ms. Cacace received B.S. from Fairfield University, obtained her Ph.D. in pharmacology from Columbia University and completed her postdoctoral training at the National Cancer Institute.

Positions